• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

UDP-吡喃半乳糖变位酶抑制作用的构象控制

Conformational Control of UDP-Galactopyranose Mutase Inhibition.

作者信息

Wangkanont Kittikhun, Winton Valerie J, Forest Katrina T, Kiessling Laura L

机构信息

Department of Chemistry, ‡Department of Biochemistry, and §Department of Bacteriology, University of Wisconsin-Madison , Madison, Wisconsin 53706, United States.

出版信息

Biochemistry. 2017 Aug 1;56(30):3983-3992. doi: 10.1021/acs.biochem.7b00189. Epub 2017 Jul 20.

DOI:10.1021/acs.biochem.7b00189
PMID:28608671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5739916/
Abstract

UDP-galactopyranose mutase (Glf or UGM) catalyzes the formation of uridine 5'-diphosphate-α-d-galactofuranose (UDP-Galf) from UDP-galactopyranose (UDP-Galp). The enzyme is required for the production of Galf-containing glycans. UGM is absent in mammals, but members of the Corynebacterineae suborder require UGM for cell envelope biosynthesis. The need for UGM in some pathogens has prompted the search for inhibitors that could serve as antibiotic leads. Optimizing inhibitor potency, however, has been challenging. The UGM from Klebsiella pneumoniae (KpUGM), which is not required for viability, is more effectively impeded by small-molecule inhibitors than are essential UGMs from species such as Mycobacterium tuberculosis or Corynebacterium diphtheriae. Why KpUGM is more susceptible to inhibition than other orthologs is not clear. One potential source of difference is UGM ortholog conformation. We previously determined a structure of CdUGM bound to a triazolothiadiazine inhibitor in the open form, but it was unclear whether the small-molecule inhibitor bound this form or to the closed form. By varying the terminal tag (CdUGM-His and GSG-CdUGM), we crystallized CdUGM to capture the enzyme in different conformations. These structures reveal a pocket in the active site that can be exploited to augment inhibitor affinity. Moreover, they suggest the inhibitor binds the open form of most prokaryotic UGMs but can bind the closed form of KpUGM. This model and the structures suggest strategies for optimizing inhibitor potency by exploiting UGM conformational flexibility.

摘要

UDP-吡喃半乳糖变位酶(Glf或UGM)催化由UDP-吡喃半乳糖(UDP-Galp)形成尿苷5'-二磷酸-α-D-呋喃半乳糖(UDP-Galf)。该酶是含Galf聚糖产生所必需的。UGM在哺乳动物中不存在,但棒杆菌亚目成员的细胞包膜生物合成需要UGM。一些病原体对UGM的需求促使人们寻找可作为抗生素先导物的抑制剂。然而,优化抑制剂效力一直具有挑战性。肺炎克雷伯菌的UGM(KpUGM)对生存力不是必需的,与来自结核分枝杆菌或白喉棒状杆菌等物种的必需UGM相比,小分子抑制剂对其的抑制作用更有效。KpUGM为何比其他直系同源物更容易受到抑制尚不清楚。一个潜在的差异来源是UGM直系同源物的构象。我们之前确定了处于开放形式的与三唑并噻二嗪抑制剂结合的CdUGM的结构,但尚不清楚小分子抑制剂是结合这种形式还是封闭形式。通过改变末端标签(CdUGM-His和GSG-CdUGM),我们使CdUGM结晶以捕获处于不同构象的酶。这些结构揭示了活性位点中的一个口袋,可利用该口袋来增强抑制剂亲和力。此外,它们表明抑制剂结合大多数原核UGM的开放形式,但可以结合KpUGM的封闭形式。该模型和这些结构提出了通过利用UGM构象灵活性来优化抑制剂效力的策略。

相似文献

1
Conformational Control of UDP-Galactopyranose Mutase Inhibition.UDP-吡喃半乳糖变位酶抑制作用的构象控制
Biochemistry. 2017 Aug 1;56(30):3983-3992. doi: 10.1021/acs.biochem.7b00189. Epub 2017 Jul 20.
2
Chemoenzymatic synthesis, inhibition studies, and X-ray crystallographic analysis of the phosphono analog of UDP-Galp as an inhibitor and mechanistic probe for UDP-galactopyranose mutase.酶促化学合成、抑制研究及 UDP-Galp 膦酸类似物的 X 射线晶体学分析作为 UDP-半乳糖吡喃糖变位酶的抑制剂和作用机制探针。
J Mol Biol. 2010 Nov 5;403(4):578-90. doi: 10.1016/j.jmb.2010.08.053. Epub 2010 Sep 17.
3
Site-directed mutagenesis of UDP-galactopyranose mutase reveals a critical role for the active-site, conserved arginine residues.尿苷二磷酸半乳糖吡喃糖变位酶的定点诱变揭示了活性位点保守精氨酸残基的关键作用。
Biochemistry. 2007 Jun 12;46(23):6723-32. doi: 10.1021/bi7002795. Epub 2007 May 19.
4
Structural basis of ligand binding to UDP-galactopyranose mutase from Mycobacterium tuberculosis using substrate and tetrafluorinated substrate analogues.结核分枝杆菌 UDP-半乳糖吡喃糖变位酶与配体结合的结构基础:使用底物和全氟化底物类似物。
J Am Chem Soc. 2015 Jan 28;137(3):1230-44. doi: 10.1021/ja511204p. Epub 2015 Jan 16.
5
Ligand binding and substrate discrimination by UDP-galactopyranose mutase.UDP-吡喃半乳糖变位酶的配体结合与底物识别
J Mol Biol. 2009 Aug 14;391(2):327-40. doi: 10.1016/j.jmb.2009.05.081. Epub 2009 Jun 3.
6
Potent ligands for prokaryotic UDP-galactopyranose mutase that exploit an enzyme subsite.利用酶亚位点的原核生物UDP-吡喃半乳糖变位酶的强效配体。
Org Lett. 2009 Jan 1;11(1):193-6. doi: 10.1021/ol802094p.
7
Structural basis of substrate binding to UDP-galactopyranose mutase: crystal structures in the reduced and oxidized state complexed with UDP-galactopyranose and UDP.底物与UDP-吡喃半乳糖变位酶结合的结构基础:与UDP-吡喃半乳糖和UDP复合的还原态和氧化态晶体结构
J Mol Biol. 2009 Dec 18;394(5):864-77. doi: 10.1016/j.jmb.2009.10.013. Epub 2009 Oct 21.
8
Synthesis and biological evaluation of nonionic substrate mimics of UDP-Galp as candidate inhibitors of UDP galactopyranose mutase (UGM).UDP-半乳糖吡喃糖变位酶(UGM)候选抑制剂UDP-Galp非离子型底物类似物的合成及生物学评价
Bioorg Med Chem Lett. 2015 May 1;25(9):1995-7. doi: 10.1016/j.bmcl.2015.03.006. Epub 2015 Mar 17.
9
Substrate-dependent dynamics of UDP-galactopyranose mutase: Implications for drug design.基于底物的 UDP-半乳糖吡喃糖变位酶动力学:对药物设计的启示。
Protein Sci. 2013 Nov;22(11):1490-501. doi: 10.1002/pro.2332. Epub 2013 Sep 17.
10
Carboxylate Surrogates Enhance the Antimycobacterial Activity of UDP-Galactopyranose Mutase Probes.羧酸盐替代物增强了UDP-吡喃半乳糖变位酶探针的抗分枝杆菌活性。
ACS Infect Dis. 2016 Aug 12;2(8):538-43. doi: 10.1021/acsinfecdis.6b00021. Epub 2016 Jun 29.

引用本文的文献

1
Structural bioinformatics insights into UDP-galactopyranose mutase (UGM) as a novel drug target for antifilarial therapy against human filarial parasite Brugia malayi.基于结构生物信息学对UDP-吡喃半乳糖变位酶(UGM)的见解:作为抗人类丝虫寄生虫马来布鲁线虫抗丝虫治疗的新型药物靶点
Mol Divers. 2025 Jul 24. doi: 10.1007/s11030-025-11304-5.
2
Association between clinical-biological characteristics of Klebsiella pneumoniae and 28-day mortality in patients with bloodstream infection.肺炎克雷伯菌临床生物学特征与血流感染患者28天死亡率之间的关联。
BMC Microbiol. 2024 Dec 30;24(1):552. doi: 10.1186/s12866-024-03714-6.
3
Steric Control of the Rate-Limiting Step of UDP-Galactopyranose Mutase.

本文引用的文献

1
Comparing Galactan Biosynthesis in and .比较[具体对象1]和[具体对象2]中的半乳聚糖生物合成。
J Biol Chem. 2017 Feb 17;292(7):2944-2955. doi: 10.1074/jbc.M116.759340. Epub 2016 Dec 30.
2
Processing of X-ray diffraction data collected in oscillation mode.振荡模式下收集的X射线衍射数据的处理。
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
3
A Second, Druggable Binding Site in UDP-Galactopyranose Mutase from Mycobacterium tuberculosis?来自结核分枝杆菌的UDP-吡喃半乳糖变位酶中第二个可成药结合位点?
UDP-吡喃半乳糖变位酶限速步骤的空间控制
Biochemistry. 2018 Jul 3;57(26):3713-3721. doi: 10.1021/acs.biochem.8b00323. Epub 2018 May 18.
Chembiochem. 2016 Dec 2;17(23):2264-2273. doi: 10.1002/cbic.201600469. Epub 2016 Nov 7.
4
Carboxylate Surrogates Enhance the Antimycobacterial Activity of UDP-Galactopyranose Mutase Probes.羧酸盐替代物增强了UDP-吡喃半乳糖变位酶探针的抗分枝杆菌活性。
ACS Infect Dis. 2016 Aug 12;2(8):538-43. doi: 10.1021/acsinfecdis.6b00021. Epub 2016 Jun 29.
5
In Crystallo Capture of a Covalent Intermediate in the UDP-Galactopyranose Mutase Reaction.在晶体中捕获UDP-吡喃半乳糖变位酶反应中的共价中间体。
Biochemistry. 2016 Feb 16;55(6):833-6. doi: 10.1021/acs.biochem.6b00035. Epub 2016 Feb 4.
6
Virtual Screening for UDP-Galactopyranose Mutase Ligands Identifies a New Class of Antimycobacterial Agents.针对UDP-吡喃半乳糖变位酶配体的虚拟筛选鉴定出一类新型抗分枝杆菌药物。
ACS Chem Biol. 2015 Oct 16;10(10):2209-18. doi: 10.1021/acschembio.5b00370. Epub 2015 Aug 17.
7
Synthesis and biological evaluation of nonionic substrate mimics of UDP-Galp as candidate inhibitors of UDP galactopyranose mutase (UGM).UDP-半乳糖吡喃糖变位酶(UGM)候选抑制剂UDP-Galp非离子型底物类似物的合成及生物学评价
Bioorg Med Chem Lett. 2015 May 1;25(9):1995-7. doi: 10.1016/j.bmcl.2015.03.006. Epub 2015 Mar 17.
8
Structural basis of ligand binding to UDP-galactopyranose mutase from Mycobacterium tuberculosis using substrate and tetrafluorinated substrate analogues.结核分枝杆菌 UDP-半乳糖吡喃糖变位酶与配体结合的结构基础:使用底物和全氟化底物类似物。
J Am Chem Soc. 2015 Jan 28;137(3):1230-44. doi: 10.1021/ja511204p. Epub 2015 Jan 16.
9
DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.DFG模型:预测处于非活性状态的蛋白激酶结构以用于基于结构的II型抑制剂发现。
ACS Chem Biol. 2015 Jan 16;10(1):269-78. doi: 10.1021/cb500696t. Epub 2014 Dec 9.
10
Crystal structure of human CRMP-4: correction of intensities for lattice-translocation disorder.人CRMP-4的晶体结构:晶格平移无序强度的校正
Acta Crystallogr D Biol Crystallogr. 2014 Jun;70(Pt 6):1680-94. doi: 10.1107/S1399004714006634. Epub 2014 May 30.